AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$33.47

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.01

Enterprise value

$1.93B

?
Relative Growth: Rel. Growth: 50
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 22

Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class ...

Highlights
Agios Pharmaceuticals's gross profit has surged by 151% YoY and by 52% QoQ
The revenue has surged by 141% year-on-year and by 49% since the previous quarter
AGIO's net income has shrunk by 163% YoY but it is up by 2.7% QoQ
Agios Pharmaceuticals's EPS has shrunk by 161% YoY but it has increased by 3.3% QoQ
The quick ratio is down by 32% year-on-year and by 29% since the previous quarter
Agios Pharmaceuticals's equity has decreased by 25% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-2.16%
1 week
4.76%
1 month
-17.46%
1 year
-8.58%
YTD
22.96%
QTD
-9.81%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$98.34M
Gross profit
$90.47M
Operating income
-$459.02M
Net income
-$411.29M
Gross margin
92%
Net margin
-418.2%
AGIO's net income has shrunk by 163% YoY but it is up by 2.7% QoQ
Agios Pharmaceuticals's gross profit has surged by 151% YoY and by 52% QoQ
The operating margin has dropped by 145% year-on-year but it has increased by 35% since the previous quarter
The revenue has surged by 141% year-on-year and by 49% since the previous quarter

Price vs fundamentals

How does AGIO's price correlate with its fundamentals

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
AGIO P/E details
P/E
N/A
P/B
1.94
P/S
20.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.62
Agios Pharmaceuticals's EPS has shrunk by 161% YoY but it has increased by 3.3% QoQ
Agios Pharmaceuticals's equity has decreased by 25% YoY and by 7% QoQ
The P/B is 21% above the 5-year quarterly average of 1.6 and 8% above the last 4 quarters average of 1.8
The revenue has surged by 141% year-on-year and by 49% since the previous quarter
AGIO's P/S is 88% below its 5-year quarterly average of 172.2 and 40% below its last 4 quarters average of 33.5

Efficiency

How efficient is Agios Pharmaceuticals business performance
The ROA has plunged by 183% YoY and by 4.4% from the previous quarter
AGIO's return on equity has dropped by 182% year-on-year and by 4.7% since the previous quarter
The company's return on invested capital has shrunk by 179% YoY and by 6% QoQ
Agios Pharmaceuticals's return on sales has shrunk by 125% YoY but it has increased by 35% QoQ

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The quick ratio is down by 32% year-on-year and by 29% since the previous quarter
AGIO's current ratio is down by 29% year-on-year and by 28% since the previous quarter
The debt is 97% smaller than the equity
The debt has declined by 36% year-on-year and by 13% since the previous quarter
The debt to equity has decreased by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.